Dr Geoff Lawton has extensive experience in new medicine discovery across many therapeutic areas in both large and small companies and is a co-inventor of a marketed drug (Cilazapril). He is a former Director of Chemistry at Roche UK, and Vice-president Chemistry and Preclinical Sciences within Roche Bioscience, Palo Alto, USA. He was for five years the research member of a global therapy area strategy planning team for inflammatory diseases, aligning research with the clinical development and marketing parts of the business.From 2003 to 2007 he was founding Research Director with Lectus Therapeutics building from start-up a drug discovery organisation; generating the team, facilities and project portfolio targeting the next generation of ion channel modulating medicines. Since 2001 Geoff has provided scientific and strategic evaluation and advice on drug discovery as an independent consultant for a number small and medium sized biotech companies, CROs, VCs, academic groups and medical research charities. Geoff serves on the Board of Antabio, a French biotech company developing tomorrow’s antibacterial drugs.He is a founder of INMedD, a new medicines discovery social enterprise.

Praise for the Series:"...may the Progress in Medicinal Chemistry series continue its invaluable service..." --Chemistry and Industry"... a valuable source of reference" --British Medical Journal"...These volumes should be on the shelves of all specialist libraries which claim to cater for chemists, biologists, doctors and pharmacists and should be available to everyone interested in the contemporary controversy about drugs, drug firms and the community." --Pharmaceutical Journal"...the consistently high standards for this series have been maintained in the present volume. This volume should certainly take its place next to the previous volumes in this series in libraries devoted to medicinal chemistry and drug research..." --Journal of Medicinal Chemistry

• Preface1. Human Ether-a-go-go Related Gene (Herg): A Chemist's Perspective 2. Fluorescence Based Assays3. Selective and Combined Neurokinin Receptor Antagonists4. Muscarinic Receptor Subtype Pharmacology and Physiology5. The Transcription Factor NF-êB as Drug Target6. Recent Advances in the Search for New Antimarial Agents7. The Discovery of the CCR5 Receptor Antagonist UK-427857. A new agent for the Treatment of HIV infection and AIDS